TLR9 and colon adenocarcinoma: We hypothesize that sHDL encapsulating docetaxel chemotherapy and decorated with Toll-like receptor 9 (TLR9) agonist CpG oligonucleotide will ensure effective delivery to colon adenocarcinoma tumors, leading to suppressed tumor growth and long-term survival as compared to monotherapy delivery.